Results 31 to 40 of about 4,990 (167)
HER1-targeted 86Y-panitumumab possesses superior targeting characteristics than 86Y-cetuximab for PET imaging of human malignant mesothelioma tumors xenografts. [PDF]
PLoS ONE, 2011 Malignant mesothelioma (MM), a rare form of cancer is often associated with previous exposure to fibrous minerals, such as asbestos. Asbestos exposure increases HER1-activity and expression in pre-clinical models.
Tapan K Nayak +4 more
doaj +1 more source
A Multiepitope‐Based Lateral Flow Assay for Leprosy Antibodies
Analysis &Sensing, EarlyView.An innovative lateral flow assay for leprosy diagnosis is based on gold nanoparticles and synthetic Mycobacterium leprae epitopes conjugated to keyhole limpet hemocyanin protein to enhance antibody detection. This strategy provides a rapid, accurate, and low‐cost approach for resource‐limited settings, enabling the early detection of infection. Leprosy
Cristiane Zocatelli‐Ribeiro +7 more
wiley +1 more source
The development and characterization of a human mesothelioma in vitro 3D model to investigate immunotoxin therapy. [PDF]
PLoS ONE, 2011 Tumor microenvironments present significant barriers to penetration by antibodies and immunoconjugates. Tumor microenvironments, however, are difficult to study in vitro. Cells cultured as monolayers exhibit less resistance to therapy than those grown in
Xinran Xiang +8 more
doaj +1 more source
Cytometry Part A, EarlyView.ABSTRACT For vaccination, the mechanisms of action of antigens and of immunostimulatory pathogen‐associated molecular pattern (PAMP) adjuvants are better understood than the roles of the depot, carrier, and other formulation‐related influences. Here, we carried out cytometric studies of vaccine formulations and the effect of adjuvant formulations on B ...
Egest J. Pone +3 more
wiley +1 more source
Pharmaceutics, 2023 The availability of several bioorthogonal reactions that can proceed selectively and efficiently under physiologically relevant conditions has garnered the interest of biochemists and organic chemists alike. Bioorthogonal cleavage reactions represent the
Nisarg Soni +9 more
doaj +1 more source
Immunoconjugates: Lessons from animal models
Annals of Oncology, 1994 Monoclonal antibody-mediated cancer therapy has evolved through a challenging chain of problems and solutions. The very limited therapeutic success obtained with unarmed monoclonal antibodies has increased the interest in different antibody-based targeting strategies, and numerous preclinical and even clinical studies with immunoconjugates have now ...
S, Canevari +2 more
openaire +2 more sources
Society for Maternal‐Fetal Medicine Consult Series #76: Cancer in pregnancy
Pregnancy, Volume 2, Issue 2, March 2026.Abstract Approximately one in 1000 pregnancies is complicated by the diagnosis of cancer each year, and the incidence of cancer among reproductive‐age individuals is increasing. Management of a pregnant person with cancer can be complex and warrants a multidisciplinary approach to care.
Society for Maternal‐Fetal Medicine (SMFM) +6 more
wiley +1 more source
Novel Bioconjugate Materials: Synthesis, Characterization and Medical Applications
Advanced Healthcare Materials, Volume 14, Issue 31, December 8, 2025.This review discusses the bioconjugation of novel materials grouped under “biological”, “hybrid” and “synthetic” categories. Medical applications ranging from cancer therapy and diagnostics to optogenetics and tissue engineering are explored, and conjugation trends are highlighted as a general guide. The review concludes with a comparison of techniques
Ellie Martin +6 more
wiley +1 more source
Immunotoxins and Anticancer Drug Conjugate Assemblies: The Role of the Linkage between Components
Toxins, 2011 Immunotoxins and antibody-drug conjugates are protein-based drugs combining a target-specific binding domain with a cytotoxic domain. Such compounds are potentially therapeutic against diseases including cancer, and several clinical trials have shown ...
Luigi Cattel, Paola Brusa, Franco Dosio
doaj +1 more source
Site-specific modification of ED-B-targeting antibody using intein-fusion technology
BMC Biotechnology, 2011 Background A promising new approach in cancer therapy is the use of tumor specific antibodies coupled to cytotoxic agents. Currently these immunoconjugates are prepared by rather unspecific coupling chemistries, resulting in heterogeneous products.
Greven Simone +3 more
doaj +1 more source